175 related articles for article (PubMed ID: 32251120)
1. Racial and Geographic Disparities in Endocrine Therapy Adherence Among Younger Breast Cancer Survivors.
Heiney SP; Truman S; Babatunde OA; Felder TM; Eberth JM; Crouch E; Wickersham KE; Adams SA
Am J Clin Oncol; 2020 Jul; 43(7):504-509. PubMed ID: 32251120
[TBL] [Abstract][Full Text] [Related]
2. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.
Camacho FT; Tan X; Alcalá HE; Shah S; Anderson RT; Balkrishnan R
Medicine (Baltimore); 2017 Jun; 96(24):e7147. PubMed ID: 28614244
[TBL] [Abstract][Full Text] [Related]
3. Factors Associated with Endocrine Therapy Non-Adherence in Breast Cancer Survivors.
Spencer JC; Reeve BB; Troester MA; Wheeler SB
Psychooncology; 2020 Apr; 29(4):647-654. PubMed ID: 32048400
[TBL] [Abstract][Full Text] [Related]
4. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
[TBL] [Abstract][Full Text] [Related]
5. Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
Farias AJ; Wu WH; Du XL
BMC Cancer; 2018 Dec; 18(1):1214. PubMed ID: 30514270
[TBL] [Abstract][Full Text] [Related]
6. Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy.
Biggers A; Shi Y; Charlson J; Smith EC; Smallwood AJ; Nattinger AB; Laud PW; Neuner JM
J Clin Oncol; 2016 Dec; 34(36):4398-4404. PubMed ID: 27998232
[TBL] [Abstract][Full Text] [Related]
7. Endocrine therapy use in the twenty-first century: usage rates and temporal trends illustrate opportunities for improvement for South Carolina Medicaid women.
Bedi JS; Mayo RM; Truong K; Chen L; Dickes L; Sherrill WW; Jones K
Breast Cancer Res Treat; 2018 Oct; 171(3):759-765. PubMed ID: 29971626
[TBL] [Abstract][Full Text] [Related]
8. Understanding the Association of Type 2 Diabetes Mellitus in Breast Cancer Among African American and European American Populations in South Carolina.
Samson ME; Adams SA; Orekoya O; Hebert JR
J Racial Ethn Health Disparities; 2016 Sep; 3(3):546-54. PubMed ID: 27294746
[TBL] [Abstract][Full Text] [Related]
9. Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer.
Reeder-Hayes KE; Meyer AM; Dusetzina SB; Liu H; Wheeler SB
Breast Cancer Res Treat; 2014 Jun; 145(3):743-51. PubMed ID: 24789443
[TBL] [Abstract][Full Text] [Related]
10. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors.
Emerson MA; Achacoso NS; Benefield HC; Troester MA; Habel LA
Cancer; 2021 Jun; 127(11):1847-1856. PubMed ID: 33620753
[TBL] [Abstract][Full Text] [Related]
11. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
Farias AJ; Du XL
J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
[TBL] [Abstract][Full Text] [Related]
12. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
[TBL] [Abstract][Full Text] [Related]
13. Racial and geographic disparities in adherence and discontinuation to adjuvant endocrine therapy in Texas Medicaid-insured patients with breast cancer.
Farias AJ; Wu WH; Du XL
Med Oncol; 2018 Jun; 35(7):113. PubMed ID: 29926275
[TBL] [Abstract][Full Text] [Related]
14. Endocrine Therapy Nonadherence and Discontinuation in Black and White Women.
Wheeler SB; Spencer J; Pinheiro LC; Murphy CC; Earp JA; Carey L; Olshan A; Tse CK; Bell ME; Weinberger M; Reeder-Hayes KE
J Natl Cancer Inst; 2019 May; 111(5):498-508. PubMed ID: 30239824
[TBL] [Abstract][Full Text] [Related]
15. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?
Ekinci E; Nathoo S; Korattyil T; Vadhariya A; Zaghloul HA; Niravath PA; Abughosh SM; Trivedi MV
J Cancer Surviv; 2018 Jun; 12(3):348-356. PubMed ID: 29396760
[TBL] [Abstract][Full Text] [Related]
16. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
[TBL] [Abstract][Full Text] [Related]
17. Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer.
Felder TM; Do DP; Lu ZK; Lal LS; Heiney SP; Bennett CL
Breast Cancer Res Treat; 2016 May; 157(1):193-200. PubMed ID: 27120468
[TBL] [Abstract][Full Text] [Related]
18. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
[TBL] [Abstract][Full Text] [Related]
19. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy use among Appalachian breast cancer survivors.
Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
